Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming

Area of Science:

• Oncology
• Molecular Biology
• Metabolic Pathways

Background:

• Osteosarcoma treatment outcomes have stagnated despite aggressive therapies.
• Over 80% of osteosarcoma tumors exhibit p53 deletion or mutation.
• Altered p63 and p73 are also observed in p53-deficient cancers.

Purpose of the Study:

• To investigate the efficacy of Pramlintide in osteosarcoma.
• To explore the role of islet amyloid polypeptide (IAPP) and its receptors in osteosarcoma response to Pramlintide.
• To determine if targeting tumor cell metabolism can induce osteosarcoma regression.

Main Methods:

• Analysis of p53, p63, p73, and IAPP expression in osteosarcoma cells.
• Assessment of IAPP receptor (CalcR, RAMP3) presence and function.
• In vitro studies evaluating Pramlintide's effect on glycolysis, proliferation, and apoptosis in osteosarcoma cells with varying glycolytic activity.
• In vivo studies using a subcutaneous osteosarcoma mouse model with intratumoral Pramlintide injection.

Main Results:

• Osteosarcoma cells exhibit altered p53, p63, p73, and decreased IAPP expression but possess functional IAPP receptors.
• Pramlintide significantly decreased glycolysis, proliferation, and increased apoptosis in osteosarcoma cells with high/mid glycolytic activity.
• Pramlintide treatment led to tumor regression in a subcutaneous osteosarcoma mouse model, evidenced by decreased Ki-67 and HIF-1α, and increased apoptosis.

Conclusions:

• Pramlintide effectively targets metabolic programming in osteosarcoma cells with specific genetic alterations and high glycolytic function.
• This metabolic modulation by Pramlintide inhibits tumor growth and induces apoptosis.
• Pramlintide represents a potential therapeutic strategy for a subset of osteosarcoma patients.